Bicycle Therapeutics Terminates Material Definitive Agreement
Ticker: BCYC · Form: 8-K · Filed: Jul 10, 2024 · CIK: 1761612
Sentiment: neutral
Topics: agreement-termination, material-event
Related Tickers: BCYC
TL;DR
BCYC terminated a major deal, watch for fallout.
AI Summary
Bicycle Therapeutics plc announced on July 9, 2024, the termination of a material definitive agreement. The company, incorporated in England and Wales, filed this 8-K report on July 10, 2024, to disclose this event.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's ongoing operations, partnerships, and financial outlook.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement can signal underlying issues with the agreement or the parties involved, potentially impacting future business and financials.
Key Players & Entities
- Bicycle Therapeutics plc (company) — Registrant
- July 9, 2024 (date) — Date of earliest event reported
- July 10, 2024 (date) — Date of report filing
FAQ
What specific material definitive agreement was terminated?
The filing does not specify which material definitive agreement was terminated, only that one was.
When did the termination of the agreement become effective?
The filing indicates July 9, 2024, as the date of the earliest event reported, implying this is when the termination occurred or was decided.
What are the potential consequences of this termination for Bicycle Therapeutics?
The filing does not detail the consequences, but such terminations can affect partnerships, revenue streams, and strategic direction.
Was this termination a mutual decision or initiated by one party?
The filing does not provide details on whether the termination was mutual or unilateral.
Are there any financial implications disclosed regarding this termination?
No specific financial implications or amounts related to the termination are disclosed in this filing.
Filing Stats: 653 words · 3 min read · ~2 pages · Grade level 12.5 · Accepted 2024-07-10 16:50:32
Key Financial Figures
- $75.0 million — an aggregate principal amount of up to $75.0 million (the "Term Loans"), of which $30.0 mill
- $30.0 million — .0 million (the "Term Loans"), of which $30.0 million was outstanding and which bore interest
- $1.5 million — paid interest, an end-of-term charge of $1.5 million and a prepayment charge of $0.3 million
- $0.3 m — $1.5 million and a prepayment charge of $0.3 million, for a total aggregate payment of
- $31.9 m — llion, for a total aggregate payment of $31.9 million, using cash on hand. As collatera
Filing Documents
- tm2419133d1_8k.htm (8-K) — 29KB
- 0001104659-24-078976.txt ( ) — 246KB
- bcyc-20240709.xsd (EX-101.SCH) — 3KB
- bcyc-20240709_def.xml (EX-101.DEF) — 26KB
- bcyc-20240709_lab.xml (EX-101.LAB) — 36KB
- bcyc-20240709_pre.xml (EX-101.PRE) — 25KB
- tm2419133d1_8k_htm.xml (XML) — 6KB
02 Termination of a Material Definitive Agreement
Item 1.02 Termination of a Material Definitive Agreement. On July 9, 2024, Bicycle Therapeutics plc (the "Company") repaid in its entirety and voluntarily terminated its loan and security agreement, dated September 30, 2020 (as amended from time to time, the "Loan Agreement"), by and among the Company, certain of its subsidiaries and Hercules Capital, Inc. ("Hercules"). The Loan Agreement provided for term loans in an aggregate principal amount of up to $75.0 million (the "Term Loans"), of which $30.0 million was outstanding and which bore interest at an annual rate equal to the prime rate as reported in the Wall Street Journal plus 4.55%, with a minimum annual rate of at least 8.05%, capped at a rate no greater than 9.05%. The Term Loans were scheduled to mature on July 1, 2025. The Company elected to repay all amounts outstanding, including accrued and unpaid interest, an end-of-term charge of $1.5 million and a prepayment charge of $0.3 million, for a total aggregate payment of $31.9 million, using cash on hand. As collateral for the obligations under the Loan Agreement, the Company granted to Hercules a senior security interest in all of Company's right, title and interest in, to and under substantially all of Company's personal property and other assets, other than its intellectual property, and, upon the termination of the Loan Agreement, all security interests granted to the secured parties thereunder were terminated and released. The Loan Agreement also included customary affirmative and restrictive covenants, representations and warranties and events of default, as more fully set forth in the Loan Agreement.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 10, 2024 Bicycle Therapeutics plc By: /s/ Alethia Young Name: Alethia Young Title: Chief Financial Officer